Therapy Detail

Therapy Name Paclitaxel + Rebastinib
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Paclitaxel Taxol 7-Epipaclitaxel Antimicrotubule Agent 12 BCL2 Family Inhibitor 6 Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).
Rebastinib DCC-2036 BCR-ABL Inhibitor 24 FLT3 Inhibitor 50 TIE2 Inhibitor 1 VEGFR2 Inhibitor 34 Rebastinib (DCC-2036) inhibits BCR-ABL1 and ABL1 mutations including T315I, and has some activity against TIE-2, FLT3, and VEGFR2, potentially resulting in decreased tumor cell growth (PMID: 21481795).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT02824575 Phase I Paclitaxel + Rebastinib Eribulin + Rebastinib Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer Recruiting
NCT03601897 Phase I Paclitaxel + Rebastinib A Safety, Tolerability and PK Study of Rebastinib in Patients With Advanced Solid Tumors Recruiting